InMed Pharmaceuticals Inc. (INM)

InMed Pharmaceuticals Inc. (INM) Healthcare & Pipeline Overview

InMed Pharmaceuticals Inc. is a clinical-stage biotechnology firm based in Vancouver, Canada, specializing in the research and development of cannabinoid-based pharmaceutical treatments. With a lead product, INM-755, in Phase I trials for epidermolysis bullosa, and a proprietary biosynthesis platform, the company aims to address unmet medical needs in dermatology, ocular diseases, and pain management.

What Is the Investment Thesis for INM?

InMed Pharmaceuticals Inc. presents a research-driven investment thesis centered on its clinical-stage pipeline of cannabinoid-based therapies and its proprietary manufacturing technology. The company's lead asset, INM-755, is in a second Phase I clinical trial for epidermolysis bullosa, representing a potential first-in-class treatment for a rare disease with significant unmet medical needs. Successful progression through clinical development for INM-755, along with preclinical candidates INM-088 for glaucoma and INM-405 for pain, could unlock substantial value. The IntegraSyn biosynthesis platform offers a scalable and potentially cost-effective method for producing pharmaceutical-grade cannabinoids, providing a strategic advantage in a nascent therapeutic area. While the company currently operates with a negative profit margin of -246.4% and a market capitalization of $2.99M, typical for a clinical-stage biotech, its gross margin of 30.4% suggests some operational efficiency in its current activities. The collaboration with BayMedica Inc. further enhances its capabilities in novel cannabinoid development. Key value drivers include positive clinical trial readouts, regulatory milestones, and the commercialization potential of its drug candidates, supported by a unique manufacturing approach.

Based on FMP financials and quantitative analysis

INM Key Highlights

• InMed Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on cannabinoid-based therapies, with its lead product INM-755 currently in a second Phase I clinical trial for epidermolysis bullosa.
• The company reported a gross margin of 30.4%, indicating efficiency in its current research and development operations despite its clinical stage.
• With a profit margin of -246.4%, InMed reflects the typical financial profile of a biotechnology company heavily investing in research and development prior to commercialization.
• InMed is developing a proprietary IntegraSyn biosynthesis platform for manufacturing pharmaceutical-grade cannabinoids, aiming for scalable and consistent production.
• The company maintains a focused team of 13 employees, headquartered in Vancouver, Canada, driving its specialized cannabinoid drug development efforts.

Who Are INM's Competitors?

INM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INM's Key Strengths?

• Diverse clinical pipeline with lead product INM-755 in a second Phase I trial for epidermolysis bullosa.
• Proprietary IntegraSyn biosynthesis platform for scalable and high-quality cannabinoid manufacturing.
• Strategic research collaboration with BayMedica Inc. for novel cannabinoid development.
• Focused expertise in cannabinoid-based therapies for specific medical conditions like dermatology and ocular diseases.

What Are INM's Weaknesses?

• Clinical-stage company with no commercialized products, leading to a negative profit margin of -246.4%.
• Small employee base of 13, potentially limiting the scope and speed of multiple development programs.
• Market capitalization of $2.99M indicates a very early-stage or micro-cap company, potentially facing funding challenges.
• High reliance on successful clinical trial outcomes for pipeline validation and future commercial viability.

What Could Drive INM Stock Higher?

• Positive clinical data readout and successful advancement of INM-755 from its second Phase I trial into subsequent clinical phases for epidermolysis bullosa.
• Initiation of human clinical trials for INM-088 (glaucoma) or INM-405 (pain), moving these preclinical candidates closer to commercialization.
• Further development and validation of the IntegraSyn biosynthesis platform, demonstrating its scalability and efficiency for pharmaceutical-grade cannabinoid production.
• Expansion or new therapeutic discoveries resulting from the research collaboration agreement with BayMedica Inc., potentially broadening the company's pipeline.
• Achievement of key regulatory milestones, such as IND (Investigational New Drug) application approvals for pipeline candidates.

What Are the Key Risks for INM?

• Financial-distress signal — its Altman Z-Score of -20.42 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-72.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Significant R&D expenses contributing to a negative profit margin of -246.4%, necessitating continuous capital raises to fund operations.
• Clinical trial failures or unexpected adverse events for INM-755, INM-088, or INM-405, which could halt or delay drug development.
• Stringent and evolving regulatory landscape for cannabinoid-based therapies, potentially leading to delays or denial of market approvals.
• High dependence on the successful development and commercialization of a limited number of pipeline candidates, particularly INM-755.
• Intense competition from other pharmaceutical and biotechnology companies developing similar or alternative treatments for targeted indications.

What Are the Growth Opportunities for INM?

• Growth opportunity 1: Advancement of INM-755 for Epidermolysis Bullosa. The successful progression of INM-755, a cannabinol topical cream, through its second Phase I clinical trial and into subsequent phases for epidermolysis bullosa represents a significant growth driver. Epidermolysis bullosa is a rare genetic disorder with substantial unmet medical needs, implying a high potential market value for an effective treatment. Positive clinical data and eventual regulatory approval could establish INM-755 as a leading therapy, capturing a substantial share of this specialized market. The timeline for this opportunity spans several years, contingent on trial outcomes and regulatory processes, but successful milestones would dramatically de-risk the company and enhance its valuation.
• Growth opportunity 2: Development of INM-088 for Glaucoma. InMed's preclinical program for INM-088, targeting glaucoma, offers another substantial growth avenue. Glaucoma is a leading cause of irreversible blindness globally, affecting millions, and the market for glaucoma treatments is considerable and growing. Advancing INM-088 from preclinical studies into human clinical trials would validate its therapeutic potential and attract significant investor interest. The company's focus on ocular diseases with cannabinoid-based treatments positions it within an innovative segment of ophthalmology. This opportunity has a longer timeline, as it is in earlier stages of development, but successful progression could tap into a large patient population.
• Growth opportunity 3: Development of INM-405 for Pain Management. The development of INM-405 for the treatment of pain represents a broad and potentially lucrative growth opportunity. Chronic pain affects a vast number of individuals worldwide, and there is an ongoing demand for novel, effective, and safer pain management solutions, particularly amidst concerns regarding opioids. As INM-405 is in preclinical studies, its advancement into clinical trials would signify a major step towards addressing this extensive market. Success in this area could provide a significant revenue stream, given the widespread prevalence of pain conditions. The timeline for this opportunity is long-term, requiring extensive clinical validation.
• Growth opportunity 4: Expansion and Commercialization of IntegraSyn Manufacturing Platform. InMed's proprietary IntegraSyn biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids offers a strategic growth opportunity beyond its drug pipeline. This platform aims to provide a consistent, high-quality, and potentially cost-effective method for producing cannabinoids. If proven scalable and efficient, IntegraSyn could not only support InMed's internal pipeline but also become a source of revenue through partnerships or licensing to other pharmaceutical companies requiring high-purity cannabinoid active pharmaceutical ingredients. This platform could address supply chain challenges in the cannabinoid therapeutics market, creating a competitive advantage. The timeline for realizing this opportunity is ongoing, with potential for commercialization as the platform matures.
• Growth opportunity 5: Leveraging Research Collaboration with BayMedica Inc. The research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics presents a synergistic growth opportunity. This partnership allows InMed to expand its research capabilities, accelerate the discovery of new cannabinoid compounds, and potentially broaden its therapeutic pipeline without solely relying on internal resources. Successful outcomes from this collaboration could lead to the identification of new drug candidates or enhanced manufacturing efficiencies, strengthening InMed's overall market position in cannabinoid therapeutics. The timeline for this opportunity is ongoing, with potential for continuous innovation and pipeline expansion.

What Opportunities Does INM Have?

• Successful advancement of INM-755 through clinical trials and eventual regulatory approval for epidermolysis bullosa.
• Progression of preclinical candidates INM-088 (glaucoma) and INM-405 (pain) into human clinical studies.
• Expansion of the IntegraSyn platform for broader application or potential licensing to other pharmaceutical entities.
• Capitalizing on the growing scientific and medical acceptance of cannabinoid therapeutics for various indications.

What Threats Does INM Face?

• Risk of clinical trial failures or delays for INM-755 and other pipeline candidates.
• Intense competition from other biotechnology and pharmaceutical companies developing cannabinoid-based drugs.
• Significant regulatory hurdles and evolving frameworks for cannabinoid-based pharmaceuticals.
• Ongoing need for substantial capital raises to fund research and development, potentially leading to shareholder dilution.
• Intellectual property challenges and patent protection in a rapidly developing field.

What Are INM's Competitive Advantages?

• Proprietary clinical-stage drug candidates, such as INM-755, INM-088, and INM-405, targeting specific therapeutic areas.
• Development of IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids, potentially offering cost and quality advantages.
• Specialized expertise in cannabinoid science and drug development, positioning the company in a growing, yet complex, therapeutic field.
• Research collaboration with BayMedica Inc., enhancing capabilities in novel cannabinoid discovery and manufacturing.
• Early-mover advantage and established pipeline in specific cannabinoid-based indications, building a foundation of intellectual property.

What Does INM Do?

InMed Pharmaceuticals Inc., incorporated in 1981 and headquartered in Vancouver, Canada, is a clinical-stage pharmaceutical company dedicated to the research and development of cannabinoid-based therapies. Initially known as Cannabis Technologies Inc., the company rebranded to InMed Pharmaceuticals Inc. in October 2014, signaling its focused evolution into a pharmaceutical entity. The company's pipeline is centered around several promising candidates, with its lead product being INM-755, a cannabinol topical cream. This cream is currently undergoing a second Phase I clinical trial specifically for the treatment of epidermolysis bullosa, a rare and severe genetic skin disorder characterized by fragile skin that blisters and tears easily. Beyond its lead candidate, InMed is actively engaged in preclinical studies for INM-088, targeting the treatment of glaucoma, a group of eye conditions that damage the optic nerve, often due to abnormally high pressure inside the eye. Additionally, the company is developing INM-405, a compound aimed at pain management, addressing a broad and significant therapeutic area. InMed's strategic focus extends beyond these specific compounds to encompass the broader development of cannabinoid-based treatments for a range of diseases, particularly within dermatology and ocular conditions, leveraging the therapeutic potential of cannabinoids. A critical component of InMed's operational strategy is its work on IND-enabling pharmacology and preclinical toxicology studies, essential steps for advancing drug candidates toward human clinical trials. Furthermore, the company is innovating in the manufacturing space through IntegraSyn, an integrated biosynthesis-based manufacturing approach designed for the efficient and scalable synthesis of pharmaceutical-grade cannabinoids. This platform is intended to ensure a consistent and high-quality supply of active pharmaceutical ingredients for its pipeline. To bolster its manufacturing and research capabilities, InMed Pharmaceuticals Inc. maintains a research collaboration agreement with BayMedica Inc., focusing on the manufacturing and testing of novel cannabinoid therapeutics, thereby expanding its capacity for innovation and product development.

What Products and Services Does INM Offer?

• Researches and develops cannabinoid-based therapies for various diseases.
• Advances INM-755, a cannabinol topical cream, through Phase I clinical trials for epidermolysis bullosa.
• Conducts preclinical studies for INM-088, a potential treatment for glaucoma.
• Develops INM-405 for pain management, currently in preclinical stages.
• Focuses on cannabinoid-based treatments for dermatology and ocular diseases.
• Performs IND-enabling pharmacology and preclinical toxicology studies to prepare drugs for clinical trials.
• Develops IntegraSyn, a biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids.
• Collaborates with BayMedica Inc. for manufacturing and testing novel cannabinoid therapeutics.

How Does INM Make Money?

• Primarily a research and development (R&D) focused clinical-stage pharmaceutical company, investing in drug discovery and clinical trials.
• Aims to generate revenue through the successful development, regulatory approval, and commercialization of its proprietary cannabinoid-based drug candidates.
• Potentially seeks partnerships, licensing agreements, or out-licensing opportunities for its drug candidates or its IntegraSyn manufacturing platform.
• Relies on external funding, such as equity financing or grants, to support its extensive R&D activities and clinical trial expenses.
• Focuses on developing treatments for specific, often unmet, medical needs in dermatology, ocular diseases, and pain.

What Industry Does INM Operate In?

InMed Pharmaceuticals Inc. operates within the dynamic and rapidly evolving biotechnology industry, specifically focusing on the therapeutic potential of cannabinoids. This niche segment of healthcare is characterized by significant research and development investment, stringent regulatory pathways, and high-risk, high-reward profiles. The broader biotechnology sector is driven by advancements in genomic sequencing, drug discovery technologies, and personalized medicine, with a growing interest in novel therapeutic compounds. InMed's position as a clinical-stage company means it is pre-revenue from commercial products, relying on capital for pipeline progression. The competitive landscape includes both established pharmaceutical companies exploring cannabinoid applications and a growing number of specialized biotech firms. Market trends indicate increasing scientific and medical acceptance of cannabinoids for various conditions, contingent on robust clinical evidence and regulatory approvals. InMed's strategic focus on specific indications like epidermolysis bullosa, glaucoma, and pain, coupled with its proprietary manufacturing approach, aims to carve out a distinct position within this competitive and innovative space.

Who Are INM's Key Customers?

• Ultimately, patients suffering from conditions like epidermolysis bullosa, glaucoma, and various forms of pain, pending regulatory approval of its therapies.
• Healthcare providers (physicians, specialists) who would prescribe InMed's approved cannabinoid-based drugs.
• Potential pharmaceutical partners interested in licensing or co-developing InMed's drug candidates or utilizing its IntegraSyn manufacturing technology.
• Research institutions and collaborators, such as BayMedica Inc., for joint development and testing of novel therapeutics.

How InMed Pharmaceuticals Inc. Is Valued

InMed Pharmaceuticals Inc. carries a market capitalization of $2.99M, placing it in the micro-cap category. Relative to its peer group, INM's quantitative score of 49/100 is below the peer average of 76/100.

ROE -73%Key Financial Metrics

Return on equity for InMed Pharmaceuticals Inc. stands at -72.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 3.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -158.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

InMed Pharmaceuticals Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.42 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project InMed Pharmaceuticals Inc. revenue of about $71.0M for fiscal 2026, with EPS near $0.00.

INM Financials

INM Latest News

INM Analyst Consensus

INM MoonshotScore

Latest InMed Pharmaceuticals Inc. Analysis

Common Questions About INM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources